Nerve growth factor and prongf simultaneously promote symmetric self-renewal, quiescence, and epithelial to mesenchymal transition to enlarge the breast cancer stem cell compartment

Stem Cells

Volumn 33, Issue 2, 2015, Pages 342-353

  Tomellini, Elisa ^a,b,c   Touil, Yasmine ^c,d   Lagadec, Chann ^a,b   Julien, Sylvain ^b,e   Ostyn, Pauline ^c   Ziental Gelus, Nathalie ^a,b   Meignan, Samuel ^a,f   Lengrand, Justine ^a,b   Adriaenssens, Eric ^b,g   Polakowska, Renata ^c   Le Bourhis, Xuefen ^a,b  

^a INSERM   (France)

^b UNIV LILLE   (France)

^c JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^d SIRIC OncoLille   (France)

^e UNIVERSITÉ DES SCIENCES ET TECHNOLOGIES DE LILLE   (France)

^f CENTRE OSCAR LAMBRET   (France)

^g INSTITUT DE BIOLOGIE DE LILLE   (France)

Author keywords

Breast cancer stem cells; Nerve growth factor; p75NTR; proNGF

Indexed keywords

NERVE GROWTH FACTOR; NEUROTROPHIN RECEPTOR P75; PRONGF PROTEIN; PROTEIN PRECURSOR; UNCLASSIFIED DRUG; NERVE GROWTH FACTOR RECEPTOR; NERVE PROTEIN; NGF PROTEIN, HUMAN; NGFR PROTEIN, HUMAN; PRO-NERVE GROWTH FACTOR, HUMAN; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER STEM CELL; CELL COMPARTMENTALIZATION; CELL PROLIFERATION; CELL RENEWAL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PLURIPOTENT STEM CELL; SCID MOUSE; STEM CELL EXPANSION; ANIMAL; AUTOCRINE EFFECT; BREAST TUMOR; HUMAN; METABOLISM; PATHOLOGY; STEM CELL NICHE; TUMOR INVASION;

MUS;

ANIMALS; AUTOCRINE COMMUNICATION; BREAST NEOPLASMS; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MICE; MICE, SCID; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; NERVE GROWTH FACTOR; NERVE TISSUE PROTEINS; PROTEIN PRECURSORS; RECEPTORS, NERVE GROWTH FACTOR; STEM CELL NICHE;

EID: 84921695004     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1849     Document Type: Article

References (62)

1. Charafe-Jauffret E, Ginestier C, Birnbaum D,. Breast cancer stem cells: Tools and models to rely on. BMC Cancer 2009; 9: 202.
2. Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100: 672-679.
3. Hanahan D, Weinberg RA,. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-674.
4. Polyak K,. Breast cancer: Origins and evolution. J Clin Invest 2007; 117: 3155-3163.
5. Bibel M, Barde YA,. Neurotrophins: Key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev 2000; 14: 2919-2937.
6. Descamps S, Lebourhis X, Delehedde M, et al. Nerve growth factor is mitogenic for cancerous but not normal human breast epithelial cells. J Biol Chem 1998; 273: 16659-16662.
7. Descamps S, Toillon RA, Adriaenssens E, et al. Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. J Biol Chem 2001; 276: 17864-17870.
8. Com E, Lagadec C, Page A, et al. Nerve growth factor receptor TrkA signaling in breast cancer cells involves Ku70 to prevent apoptosis. Mol Cell Proteomics 2007; 6: 1842-1854.
9. Adriaenssens E, Vanhecke E, Saule P, et al. Nerve growth factor is a potential therapeutic target in breast cancer. Cancer Res 2008; 68: 346-351.
10. Seidah NG, Benjannet S, Pareek S, et al. Cellular processing of the nerve growth factor precursor by the mammalian pro-protein convertases. Biochem J 1996; 314(Pt 3): 951-960.
11. Lee R, Kermani P, Teng KK, et al. Regulation of cell survival by secreted proneurotrophins. Science 2001; 294: 1945-1948.
12. Harrington AW, Leiner B, Blechschmitt C, et al. Secreted proNGF is a pathophysiological death-inducing ligand after adult CNS injury. Proc Natl Acad Sci USA 2004; 101: 6226-6230.
13. Demont Y, Corbet C, Page A, et al. Pro-nerve growth factor induces autocrine stimulation of breast cancer cell invasion through tropomyosin-related kinase A (TrkA) and sortilin protein. J Biol Chem 2012; 287: 1923-1931.
14. Nykjaer A, Lee R, Teng KK, et al. Sortilin is essential for proNGF-induced neuronal cell death. Nature 2004; 427: 843-848.
15. Vaegter CB, Jansen P, Fjorback AW, et al. Sortilin associates with Trk receptors to enhance anterograde transport and neurotrophin signaling. Nat Neurosci 2011; 14: 54-61.
16. Betters E, Liu Y, Kjaeldgaard A, et al. Analysis of early human neural crest development. Dev Biol 2010; 344: 578-592.
17. Tomellini E, Lagadec C, Polakowska R, et al. Role of p75 neurotrophin receptor in stem cell biology: More than just a marker. Cell Mol Life Sci 2014; 71: 2467-2481.
18. Mikami Y, Ishii Y, Watanabe N, et al. CD271/p75(NTR) inhibits the differentiation of mesenchymal stem cells into osteogenic, adipogenic, chondrogenic, and myogenic lineages. Stem Cells Dev 2011; 20: 901-913.
19. Okumura T, Shimada Y, Imamura M, et al. Neurotrophin receptor p75(NTR) characterizes human esophageal keratinocyte stem cells in vitro. Oncogene 2003; 22: 4017-4026.
20. Li X, Shen Y, Di B, et al. Biological and clinical significance of p75NTR expression in laryngeal squamous epithelia and laryngocarcinoma. Acta Otolaryngol 2012; 132: 314-324.
21. Nakamura T, Endo K, Kinoshita S,. Identification of human oral keratinocyte stem/progenitor cells by neurotrophin receptor p75 and the role of neurotrophin/p75 signaling. Stem Cells 2007; 25: 628-638.
22. Truzzi F, Marconi A, Atzei P, et al. p75 neurotrophin receptor mediates apoptosis in transit-amplifying cells and its overexpression restores cell death in psoriatic keratinocytes. Cell Death Differ 2011; 18: 948-958.
23. Di Girolamo N, Sarris M, Chui J, et al. Localization of the low-affinity nerve growth factor receptor p75 in human limbal epithelial cells. J Cell Mol Med 2008; 12(6B): 2799-2811.
24. Kim J, Villadsen R, Sørlie T, et al. Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity. Proc Natl Acad Sci USA 2012; 109: 6124-6129.
25. Touil Y, Zuliani T, Wolowczuk I, et al. The PI3K/AKT signaling pathway controls the quiescence of the low-Rhodamine123-retention cell compartment enriched for melanoma stem cell activity. STEM CELLS 2012; 31: 641-651.
26. Ostyn P, El-Machhour R, Begard S, et al. Transient TNF regulates the self-renewing capacity of stem-like label-retaining cells in sphere and skin equivalent models of melanoma. Cell Commun Signal 2014; 12: 52.
27. Pluijm G, van der, Sijmons B, Vloedgraven H, et al. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: Elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases. J Bone Miner Res 2001; 16: 1077-1091.
28. Gebäck T, Schulz MMP, Koumoutsakos P, et al. TScratch: A novel and simple software tool for automated analysis of monolayer wound healing assays. Biotechniques 2009; 46: 265-274.
29. Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003; 17: 1253-1270.
30. Barrandon Y, Green H,. Three clonal types of keratinocyte with different capacities for multiplication. Proc Natl Acad Sci USA 1987; 84: 2302-2306.
31. Moreb JS,. Aldehyde dehydrogenase as a marker for stem cells. Curr Stem Cell Res Ther 2008; 3: 237-246.
32. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-567.
33. Morimoto K, Kim SJ, Tanei T, et al. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci 2009; 100: 1062-1068.
34. Taurin S, Sandbo N, Qin Y, et al. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem 2006; 281: 9971-9976.
35. Saito-Diaz K, Chen TW, Wang X, et al. The way Wnt works: Components and mechanism. Growth Factors 2013; 31: 1-31.
36. Verbeke S, Meignan S, Lagadec C, et al. Overexpression of p75(NTR) increases survival of breast cancer cells through p21(waf1). Cell Signal 2010; 22: 1864-1873.
37. Verbeke S, Tomellini E, Dhamani F, et al. Extracellular cleavage of the p75 neurotrophin receptor is implicated in its pro-survival effect in breast cancer cells. FEBS Lett 2013; 587: 2591-2596.
38. Touil Y, Igoudjil W, Corvaisier M, et al. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Clin Cancer Res 2014; 20: 837-846.
39. Che S-M, Zhang X-Z, Liu X-L, et al. The radiosensitization effect of NS398 on esophageal cancer stem cell-like radioresistant cells. Dis Esophagus 2011; 24: 265-273.
40. Tumbar T, Guasch G, Greco V, et al. Defining the epithelial stem cell niche in skin. Science 2004; 303: 359-363.
41. Clevers H,. Stem cells, asymmetric division and cancer. Nat Genet 2005; 37: 1027-1028.
42. Knoblich JA,. Asymmetric cell division: Recent developments and their implications for tumour biology. Nat Rev Mol Cell Biol 2010; 11: 849-860.
43. Verga Falzacappa MV, Ronchini C, Reavie LB, et al. Regulation of self-renewal in normal and cancer stem cells. FEBS J 2012; 279: 3559-3572.
44. Morrison SJ, Kimble J,. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 2006; 441: 1068-1074.
45. Pece S, Tosoni D, Confalonieri SM, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010; 140: 62-73.
46. Morrison SJ, Kimble J,. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature. 2006; 441: 1068-1074.
47. Tsunekawa Y, Osumi N,. How to keep proliferative neural stem/progenitor cells: A critical role of asymmetric inheritance of cyclin D2. Cell Cycle 2012; 11: 3550-3554.
48. Tsunekawa Y, Britto JM, Takahashi M, et al. Cyclin D2 in the basal process of neural progenitors is linked to non-equivalent cell fates. EMBO J 2012; 31: 1879-1892.
49. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
50. Fillmore CM, Kuperwasser C,. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10: R25.
51. Wicha MS,. Migratory gene expression signature predicts poor patient outcome: Are cancer stem cells to blame? Breast Cancer Res 2012; 14: 114.
52. Chaffer CL, Marjanovic ND, Lee T, et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013; 154: 61-74.
53. Mani SA, Guo W, Liao M-J, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
54. Thiery JP, Acloque H, Huang RYJ, et al. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
55. Dollé L, El Yazidi-Belkoura I, Adriaenssens E, et al. Nerve growth factor overexpression and autocrine loop in breast cancer cells. Oncogene 2003; 22: 5592-5601.
56. Pece S, Serresi M, Santolini E, et al. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol 2004; 167: 215-221.
57. Rennstam K, McMichael N, Berglund P, et al. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer. Breast Cancer Res Treat 2010; 122: 315-324.
58. Guo W, Keckesova Z, Donaher JL, et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 2012; 148: 1015-1028.
59. Herreros-Villanueva M, Zhang J-S, Koenig A, et al. SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Oncogenesis 2013; 2: e61.
60. Fingleton B,. Matrix metalloproteinases: Roles in cancer and metastasis. Front Biosci 2006; 11: 479-491.
61. Cheng M, Watson PH, Paterson JA, et al. Pro-protein convertase gene expression in human breast cancer. Int J Cancer 1997; 71: 966-971.
62. Koensgen D, Mustea A, Denkert C, et al. Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer. Anticancer Res 2006; 26: 1683-1689.